UK pharmaceutical giant GSK announced yesterday that its Covid-19 therapy is effective against the Omicron variant, sending its stocks up to 1,578p. According to preliminary studies, Sotrovimab works against Omicron and its 37 mutations identified in the spike protein. "From the outset of our collaboration with Vir we hypothesised that sotrovimab would have a high barrier to resistance and thus could deliver best-in-class potential for the early treatment of patients with Covid-19," said Dr Hal Barron, KSG's chief scientific officer. Shares of airlines such as Easyjet and British Airways's owner IAG jumped on Monday and yesterday as carriers shrugged off Omicron concerns despite the return of travel restrictions.

(c) 2021 City A.M., source Newspaper